SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...

Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid ...

EST Aptevo Therapeutics (APVO) trading resumesPick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing ...

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in ...

Stock analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the ...

Aptevo Therapeutics (APVO) announced additional details about the Company’s preclinical bispecific antibody, APVO442, differentiated to target prostate cancer with enhanced precision and ...

Ladenburg Thalmann has recently initiated Aptevo Therapeutics Inc (APVO) stock to Buy rating, as announced on November 5, 2018, according to Finviz. Analyst ratings are significant because they ...

SEATTLE - Aptevo Therapeutics Inc . (NASDAQ:APVO), a biotechnology firm specializing in pharmaceutical preparations, announced a reverse stock split of its common stock, effective as of Tuesday.

Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, ...